All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-06-12T16:13:43.000Z

Rituximab maintenance lacks a clear overall survival benefit for Follicular Lymphoma

Jun 12, 2017
Share:

Bookmark this article

On 23rd May 2017, in a letter to the editor of the British Journal of Haematology, Rie S. Bech from Regionshospitalet Nordjylland, Hjørring, and Aalborg University Hospital, Aalborg, Denmark, and colleagues outlined results of their retrospective “real world” analysis of the impact of rituximab maintenance after front line immune-chemotherapy in patients with FL.

Local investigators reviewed the medical records of patients aged 18 years or older and diagnosed with FL between 2007 and 2014 in Denmark (University Hospitals of Herlev, Odense, Aarhus, and Aalborg) or London (Guy’s and St Thomas’ Hospital).

Inclusion criteria consisted of: newly diagnosed patients; grade 1–3a disease; R-CVP, R-CHOP, or R-bendamustine upfront, or after watchful waiting; and at least PR after induction therapy.

Key Highlights:

  • Overall, 239 pts included; Denmark = 208; London = 31
  • Rituximab maintenance (R+) = 160 pts; without treatment (R-) = 79 pts
  • After induction, 139 pts evaluated with PET/CT (R-, 35%; R+, 65%)
  • Mean number of rituximab maintenance treatments = 11 (IQR, 8–12) among 92/160 R+ pts
  • During follow-up, 22 pts died (R-, 13 pts; R+, 9 pts); cause of death was related to lymphoma in 5 pts (R-, 2 pts; R+, 3 pts)
  • In the R- group, 5/7 deaths reported ≤2 years after FL diagnosis were unrelated to lymphoma
  • 3-year PFS estimates in R+ vs. R- pts: 77% (95% CI, 70–85%) vs. 71% (95% CI, 61–82%); P = 0.35
  • 3-year OS estimates in R+ vs. R- pts: 97% (95% CI, 93–100%) vs. 91% (95% CI, 85–98%); P = 0.039
  • The association of better 3-year OS in R+ pts was not significant in multivariate analysis: HR = 0.33; 95% CI, 0.096–1.1; P = 0.079
  • Time to Progression (TTP) was not significantly longer for R+ pts

The group then compared their results to the phase III, randomized, controlled PRIMA study (NCT00140582). Patients in the current study were administered less rituximab maintenance (11 doses) than recommended by findings of the PRIMA study (12 doses over 2 years). Moreover, specifically in patients who completed rituximab maintenance in the current analysis, 34% were treated at intervals of 3 months instead of 2 months. It was stated that it is unknown whether tighter adherence to the PRIMA trial protocol would have benefited patients in this current analysis.

Strengths of this analysis included the thorough chart review, which eliminated the impact of incomplete data, and its “real world” nature. Undoubtedly, the small sample size was a limitation. In addition, the PFS benefit in patients receiving rituximab maintenance was unclear in the present study; the authors suggest this may be due to the lack of protocolled surveillance imaging during follow-up. 

The letter concluded by stating that, based on real world data, “the value of rituximab maintenance in FL is limited and, in the absence of clear OS benefits, remains a controversial approach.”

Abstract:

N/A

  1. Bech R.S. et al. Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1–3a follicular lymphoma. British Journal of Haematology. 2017 May 23. DOI: 10.1111/bjh.14775. [Epub ahead of print].

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox